

September 9, 2019



Soliton Releases Letter to Shareholders

Rapid Acoustic Pulse ("RAP") Technology has the Potential of Disrupting the Multi-Billion Dollar Global Aesthetics Industry

HOUSTON, Sept. 9, 2019 /PRNewswire/ -- Soliton, Inc., (Nasdaq: SOLY) ("Soliton" or the "Company"), a medical device company with a novel and proprietary platform technology licensed from The University of Texas on behalf of the MD Anderson Cancer Center ("MD Anderson"), today announced the issuance of a letter to shareholders from the Company.

"Since we closed our IPO in February of this year, we've gained over 5,000 shareholders, 25,000+ people on our email newsletter list and more than 200,000 fans on our Facebook page. In light of this, we thought it would be a perfect time to release our first shareholder letter as a public company. We believe this provides a detailed update on the Company's progress to date and the potential opportunities in our future," commented Walter Klemp, Soliton's Executive Chairman and co-founder.

The shareholder letter provides an update on the RAP (Rapid Acoustic Pulse) technology and its capabilities to address significant indications within the aesthetics industry including tattoo removal, cellulite reduction and fibrotic disorders.

To read the full shareholder letter, visit: <https://www.soliton.com>

About Soliton, Inc.

Soliton, Inc. is a medical device company with a novel and proprietary platform technology licensed from MD Anderson. The Company's first FDA cleared commercial product will use rapid pulses of acoustic shockwaves as an accessory to lasers for the removal of unwanted tattoos. The Company is based in Houston, Texas, and is actively engaged in bringing the Rapid Acoustic Pulse ("RAP") device to the market. The Company believes this "Soliton" method has the potential to lower tattoo removal costs for patients, while increasing profitability to practitioners, compared to current laser removal methods. Soliton is investigating potential additional capabilities of the RAP technology in preclinical testing, including the potential to improve fibrotic conditions such as keloid or hypertrophic scars as well as improving the appearance of cellulite by creating mechanical stress at the cellular level and inducing significant collagen growth.

For more information about the Company, please visit: <http://www.soliton.com>

Forward-Looking Statements

Some of the statements in this release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. Forward-looking statements in this press release include, without limitation, the ability of the Soliton to demonstrate efficacy and receive FDA clearance for each of the indications discussed in the Shareholder letter. These statements relate to future events, future expectations, plans and prospects. Although Soliton believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. Soliton has attempted to identify forward-looking statements by terminology including "believes," "estimates," "anticipates," "expects," "plans," "projects," "intends," "potential," "may," "could," "might," "will," "should," "approximately" or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, including those discussed under in our SEC filings, including under the heading "Item 1A. Risk Factors" in the Form 10-K for year ended December 31, 2018 we filed with the SEC and updated from time to time in our Form 10-Q filings and in our other public filings with the SEC. Any forward-looking statements contained in this release speak only as of its date. Soliton undertakes no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events.

View original content:<http://www.prnewswire.com/news-releases/soliton-releases-letter-to-shareholders-300913826.html>

SOURCE Soliton, Inc.